This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Insulet sees US Appeals Court overturn lower court injunction against Eoflow

( June 17, 2024, 15:54 GMT | Official Statement) -- MLex Summary: Insulet and Eoflow have seen the US Court of Appeals for the Federal Circuit reverse a preliminary injunction that barred Eoflow from manufacturing and marketing its EOPatch insulin delivery device. The district court failed to adequately identify specific trade secrets, address the statute of limitations, or assess whether the alleged trade secrets were already publicly available or reverse-engineered, the court said in a judgement delivered today. The appellate judges emphasized the need for precise evidence and found that Insulet had not demonstrated a likelihood of success on the merits or irreparable harm, remanding the case for further proceedings.Court document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections